RxDoctor Payments Data

Vanessa Eulo, MD

Internal Medicine · St. Louis, MONPI 1245612704

Payments from drug & device makers

What this record shows

This record is dominated by education: $463 of the $609 with a category attached, or 76.1%. It is spread thinly across 8 manufacturers, the largest accounting for just 20.2%. 2025 is the largest year on record at $214, 2.1 times the $100 reported in 2019.

$609in general payments, 2019–2025

Across 11 payments — averaging $55.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$123
  • Takeda Pharmaceuticals U.S.A., Inc.$100
  • Amgen$100
  • Astellas Pharma US Inc$95
  • AstraZeneca$68
  • Novartis$58
  • plus $65 from 2 others
$189,795in research payments, 2019–2025

Across 11 payments — averaging $17,254 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$189K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$751

What the payments were for

  • Food & beverage$14524%
  • Education$46376%

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$609 in reported general payments places this provider in the 65th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$21,990
Medicare patients
76
Services billed
264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KoselugoSelumetinib Sulfate23$544,758
Imatinib Mesylate35$29,427
EliquisApixaban47$27,929
Oxycodone Hcl58$1,815
Ondansetron Hcl30$634
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen27$441
Gabapentin42$382
Ondansetron OdtOndansetron13$311
Dexamethasone20$211
Olanzapine21$204
Duloxetine Hcl12$192
Levothyroxine Sodium20$169
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine17$160
Pregabalin11$151
Pantoprazole Sodium13$143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaKoselugo$68$544,75823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in St. Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →